Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Biotech Alert: Searches spiking for these stocks today » 11:10
12/01/22
12/01
11:10
12/01/22
11:10
OTIC

Otonomy

/

+

, CNSP

CNS Pharmaceuticals

$3.10 /

+0.07 (+2.31%)

, XFOR

X4 Pharmaceuticals

$1.38 /

-0.16 (-10.39%)

, CRBP

Corbus Pharmaceuticals

/

+

, KALA

Kala Pharmaceuticals

$5.29 /

+ (+0.00%)

These names in the…

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.38 /

-0.16 (-10.39%)

OTIC Otonomy
/

+

KALA Kala Pharmaceuticals
$5.29 /

+ (+0.00%)

CRBP Corbus Pharmaceuticals
/

+

CNSP CNS Pharmaceuticals
$3.10 /

+0.07 (+2.31%)

OTIC Otonomy
/

+

10/13/22 Piper Sandler
Otonomy downgraded to Neutral at Piper Sandler after OTO-413 fails
10/13/22 Piper Sandler
Otonomy downgraded to Neutral from Overweight at Piper Sandler
08/02/22 H.C. Wainwright
Otonomy downgraded to Neutral from Buy at H.C. Wainwright
08/01/22 Piper Sandler
Otonomy price target lowered to $3 from $6 at Piper Sandler
CNSP CNS Pharmaceuticals
$3.10 /

+0.07 (+2.31%)

08/17/22 Maxim
CNS Pharmaceuticals cut to Hold at Maxim on likely need to raise capital
08/17/22 Maxim
CNS Pharmaceuticals downgraded to Hold from Buy at Maxim
XFOR X4 Pharmaceuticals
$1.38 /

-0.16 (-10.39%)

11/30/22 H.C. Wainwright
X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright
08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
CRBP Corbus Pharmaceuticals
/

+

KALA Kala Pharmaceuticals
$5.29 /

+ (+0.00%)

11/09/22 Wedbush
Kala Pharmaceuticals price target raised to $47 from $3 at Wedbush
05/24/22 H.C. Wainwright
Kala Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright
05/17/22 H.C. Wainwright
Kala Pharmaceuticals price target lowered to $5 from $6 at H.C. Wainwright
03/30/22 Northland
Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
XFOR X4 Pharmaceuticals
$1.38 /

-0.16 (-10.39%)

KALA Kala Pharmaceuticals
$5.29 /

+ (+0.00%)

XFOR X4 Pharmaceuticals
$1.38 /

-0.16 (-10.39%)

OTIC Otonomy
/

+

KALA Kala Pharmaceuticals
$5.29 /

+ (+0.00%)

CRBP Corbus Pharmaceuticals
/

+

Wednesday
Recommendations
X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright » 06:07
11/30/22
11/30
06:07
11/30/22
06:07
XFOR

X4 Pharmaceuticals

$1.84 /

+0.08 (+4.55%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on X4 Pharmaceuticals to $5 from $3.50 and keeps a Buy rating on the shares. The company announced positive top-line data from the Phase 3 randomized, placebo-controlled, 4WHIM study, Ramakanth tells investors in a research note. The anlayst is encouraged by the positive top-line data and increased the launch probability of mavorixafor as a treatment for WHIM syndrome to 60% from 48.5%.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.84 /

+0.08 (+4.55%)

XFOR X4 Pharmaceuticals
$1.84 /

+0.08 (+4.55%)

08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
04/05/22 Canaccord
X4 Pharmaceuticals price target lowered to $10 from $20 at Canaccord
XFOR X4 Pharmaceuticals
$1.84 /

+0.08 (+4.55%)

XFOR X4 Pharmaceuticals
$1.84 /

+0.08 (+4.55%)

Tuesday
On The Fly
Fly Intel: After-Hours Movers » 19:32
11/29/22
11/29
19:32
11/29/22
19:32
WDAY

Workday

$143.37 /

-1.98 (-1.36%)

, HPE

HP Enterprise

$15.46 /

-0.1 (-0.64%)

, CRWD

Crowdstrike

$137.99 /

-1.6 (-1.15%)

, NTAP

NetApp

$71.72 /

-0.87 (-1.20%)

, INTU

Intuit

$381.14 /

-4.82 (-1.25%)

, XFOR

X4 Pharmaceuticals

$1.84 /

+0.08 (+4.55%)

Check out this evening's…

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.84 /

+0.08 (+4.55%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

NTAP NetApp
$71.72 /

-0.87 (-1.20%)

INTU Intuit
$381.14 /

-4.82 (-1.25%)

HPE HP Enterprise
$15.46 /

-0.1 (-0.64%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

11/29/22 KeyBanc
Workday price target lowered to $195 from $207 at KeyBanc
11/22/22 DA Davidson
Workday price target lowered to $205 from $220 at DA Davidson
11/21/22 BMO Capital
Workday price target lowered to $195 from $217 at BMO Capital
11/21/22 Loop Capital
Workday downgraded to Hold from Buy at Loop Capital
HPE HP Enterprise
$15.46 /

-0.1 (-0.64%)

11/22/22 UBS
Dell Technologies price target lowered to $60 from $65 at UBS
10/20/22 Citi
HP Enterprise price target lowered to $11.50 from $13.50 at Citi
10/20/22 Barclays
HP Enterprise price target lowered to $17 from $19 at Barclays
10/18/22 KGI Securities
HP Enterprise downgraded to Neutral from Outperform at KGI Securities
CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

11/28/22 RBC Capital
Crowdstrike price target lowered to $200 from $236 at RBC Capital
11/23/22 MKM Partners
Crowdstrike price target lowered to $200 from $240 at MKM Partners
11/22/22 Morgan Stanley
Crowdstrike price target lowered to $190 from $217 at Morgan Stanley
11/18/22 Barclays
Crowdstrike price target lowered to $180 from $225 at Barclays
NTAP NetApp
$71.72 /

-0.87 (-1.20%)

10/31/22 Jefferies
NetApp initiated with a Buy at Jefferies
09/19/22 Susquehanna
NetApp downgraded to Neutral at Susquehanna on downside risk to FY24 view
09/19/22 Susquehanna
NetApp downgraded to Neutral from Positive at Susquehanna
INTU Intuit
$381.14 /

-4.82 (-1.25%)

11/28/22 KeyBanc
Intuit price target lowered to $450 from $525 at KeyBanc
11/21/22 Credit Suisse
Intuit initiated with an Outperform at Credit Suisse
11/21/22 BMO Capital
Intuit price target lowered to $467 from $533 at BMO Capital
11/18/22 Barclays
Intuit price target lowered to $490 from $502 at Barclays
XFOR X4 Pharmaceuticals
$1.84 /

+0.08 (+4.55%)

08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
04/05/22 Canaccord
X4 Pharmaceuticals price target lowered to $10 from $20 at Canaccord
XFOR X4 Pharmaceuticals
$1.84 /

+0.08 (+4.55%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

NTAP NetApp
$71.72 /

-0.87 (-1.20%)

INTU Intuit
$381.14 /

-4.82 (-1.25%)

HPE HP Enterprise
$15.46 /

-0.1 (-0.64%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

  • 30
    Nov
INTU Intuit
$381.14 /

-4.82 (-1.25%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

NTAP NetApp
$71.72 /

-0.87 (-1.20%)

INTU Intuit
$381.14 /

-4.82 (-1.25%)

HPE HP Enterprise
$15.46 /

-0.1 (-0.64%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

NTAP NetApp
$71.72 /

-0.87 (-1.20%)

INTU Intuit
$381.14 /

-4.82 (-1.25%)

HPE HP Enterprise
$15.46 /

-0.1 (-0.64%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

Hot Stocks
X4 Pharmaceuticals announces 4WHIM trial meets primary endpoint » 16:05
11/29/22
11/29
16:05
11/29/22
16:05
XFOR

X4 Pharmaceuticals

$1.82 /

+0.06 (+3.41%)

X4 Pharmaceuticals…

X4 Pharmaceuticals announced top-line results from the global, pivotal Phase 3 clinical trial, or 4WHIM, of its lead investigational therapy, mavorixafor, a novel CXCR4 antagonist, in people with WHIM syndrome. 4WHIM met its primary endpoint, with mavorixafor achieving clinical and statistical superiority over placebo when measuring TATANC, or the length of time that participants' absolute neutrophil counts, or ANC, remained above a clinically meaningful threshold of 500 cells per microliter over 24-hour periods at four time points throughout the 52-week trial. Mean TATANC, was 15.04 hours in the treatment group versus 2.75 hours in the placebo group. 4WHIM also met a key secondary endpoint, with mavorixafor achieving clinical and statistical superiority over placebo when measuring TATALC, or the length of time that participants' absolute lymphocyte counts, or ALC, remained above a clinically meaningful threshold of 1,000 cells per microliter, over 24-hour periods at four time points throughout the 52-week trial. Mean TATALC was 15.80 hours in the treatment group versus 4.55 hours in the placebo group. Increases in both TATANC and TATALC were maintained versus placebo and baseline across 52 weeks, demonstrating durability of treatment effect during the trial. Mavorixafor was generally well tolerated in the trial, with no treatment-related serious adverse events reported and no discontinuations for safety events. Following completion of the placebo-controlled portion of the trial, more than 90% of the eligible participants opted to receive treatment with mavorixafor in the open-label trial extension. Additional data review and analysis of the secondary and exploratory endpoints of the 4WHIM trial are ongoing, with plans to present detailed results at a future medical meeting.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.82 /

+0.06 (+3.41%)

XFOR X4 Pharmaceuticals
$1.82 /

+0.06 (+3.41%)

08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
04/05/22 Canaccord
X4 Pharmaceuticals price target lowered to $10 from $20 at Canaccord
XFOR X4 Pharmaceuticals
$1.82 /

+0.06 (+3.41%)

Over a month ago
Hot Stocks
X4 Pharmaceuticals Chief Medical Officer, Dr. Diego Cadavid, to depart » 06:18
11/03/22
11/03
06:18
11/03/22
06:18
XFOR

X4 Pharmaceuticals

$1.95 /

+0.04 (+2.09%)

X4 announced that its…

X4 announced that its Chief Medical Officer, Dr. Diego Cadavid, intends to depart the company by the end of 2022, but will continue to support X4 as a consultant. Dr. Cadavid, still a practicing neurologist, is leaving to pursue an opportunity that closely aligns with his commitment to patients with intractable CNS disorders. X4 is appointing Dr. Murray Stewart as interim Chief Medical Officer while it conducts a search for a permanent replacement for Dr. Cadavid.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.95 /

+0.04 (+2.09%)

XFOR X4 Pharmaceuticals
$1.95 /

+0.04 (+2.09%)

08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
04/05/22 Canaccord
X4 Pharmaceuticals price target lowered to $10 from $20 at Canaccord
XFOR X4 Pharmaceuticals
$1.95 /

+0.04 (+2.09%)

Earnings
X4 Pharmaceuticals reports Q3 EPS (26c), consensus (30c) » 06:17
11/03/22
11/03
06:17
11/03/22
06:17
XFOR

X4 Pharmaceuticals

$1.95 /

+0.04 (+2.09%)

X4 had $81.1M in cash,…

X4 had $81.1M in cash, cash equivalents, and restricted cash as of September 30. X4 believes that it has sufficient funds to support company operations into the third quarter of 2023.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.95 /

+0.04 (+2.09%)

XFOR X4 Pharmaceuticals
$1.95 /

+0.04 (+2.09%)

08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
04/05/22 Canaccord
X4 Pharmaceuticals price target lowered to $10 from $20 at Canaccord
XFOR X4 Pharmaceuticals
$1.95 /

+0.04 (+2.09%)

Hot Stocks
X4 Pharmaceuticals appoints Baldry as Chief Commercial Officer » 08:09
10/26/22
10/26
08:09
10/26/22
08:09
XFOR

X4 Pharmaceuticals

$1.98 /

+0.08 (+4.21%)

, FRLN

Freeline

/

+

, WVE

Wave Life Sciences

$4.54 /

+0.295 (+6.95%)

X4 Pharmaceuticals (XFOR)…

X4 Pharmaceuticals (XFOR) announced the appointment of Mark Baldry to the position of Chief Commercial Officer. In this key role, Baldry will lead all pre-commercial and product launch efforts for the company's lead therapeutic candidate, mavorixafor, a small molecule being developed as a once-daily oral therapy for chronic neutropenic disorders, including WHIM syndrome. Baldry's previous roles include Chief Commercial Officer of Freeline Therapeutics Holdings (FRLN) and Chief Commercial Officer of Wave Life Sciences (WVE).

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.98 /

+0.08 (+4.21%)

WVE Wave Life Sciences
$4.54 /

+0.295 (+6.95%)

FRLN Freeline
/

+

XFOR X4 Pharmaceuticals
$1.98 /

+0.08 (+4.21%)

08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
04/05/22 Canaccord
X4 Pharmaceuticals price target lowered to $10 from $20 at Canaccord
FRLN Freeline
/

+

08/22/22 H.C. Wainwright
Freeline price target lowered to $15 from $20 at H.C. Wainwright
08/11/22 BTIG
Freeline price target lowered to $5 from $10 at BTIG
06/13/22 Wedbush
Sangamo assumed with a Neutral, $5 price target at Wedbush
02/01/22 Morgan Stanley
Morgan Stanley downgrades Freeline ahead of 'year of pipeline execution'
WVE Wave Life Sciences
$4.54 /

+0.295 (+6.95%)

05/13/22 H.C. Wainwright
Wave Life Sciences price target lowered to $8 from $10 at H.C. Wainwright
03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
XFOR X4 Pharmaceuticals
$1.98 /

+0.08 (+4.21%)

WVE Wave Life Sciences
$4.54 /

+0.295 (+6.95%)

FRLN Freeline
/

+

Conference/Events
X4 Pharmaceuticals management to meet virtually with Oppenheimer » 04:55
10/25/22
10/25
04:55
10/25/22
04:55
XFOR

X4 Pharmaceuticals

$1.89 /

-0.1 (-5.03%)

Virtual Meetings to be…

Virtual Meetings to be held on October 24-25 hosted by Oppenheimer.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.89 /

-0.1 (-5.03%)

XFOR X4 Pharmaceuticals
$1.89 /

-0.1 (-5.03%)

08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
04/05/22 Canaccord
X4 Pharmaceuticals price target lowered to $10 from $20 at Canaccord
XFOR X4 Pharmaceuticals
$1.89 /

-0.1 (-5.03%)

Conference/Events
X4 Pharmaceuticals management to meet virtually with Oppenheimer » 04:55
10/24/22
10/24
04:55
10/24/22
04:55
XFOR

X4 Pharmaceuticals

$1.99 /

+0.15 (+8.15%)

Virtual Meetings to be…

Virtual Meetings to be held on October 24-25 hosted by Oppenheimer.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.99 /

+0.15 (+8.15%)

XFOR X4 Pharmaceuticals
$1.99 /

+0.15 (+8.15%)

08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
04/05/22 Canaccord
X4 Pharmaceuticals price target lowered to $10 from $20 at Canaccord
XFOR X4 Pharmaceuticals
$1.99 /

+0.15 (+8.15%)

Conference/Events
X4 Pharmaceuticals management to meet virtually with Oppenheimer » 15:55
10/17/22
10/17
15:55
10/17/22
15:55
XFOR

X4 Pharmaceuticals

$2.00 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held on October 24-25 hosted by Oppenheimer.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$2.00 /

+ (+0.00%)

XFOR X4 Pharmaceuticals
$2.00 /

+ (+0.00%)

08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
04/05/22 Canaccord
X4 Pharmaceuticals price target lowered to $10 from $20 at Canaccord
XFOR X4 Pharmaceuticals
$2.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.